# Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05506332** · PHASE1 · RECRUITING · sponsor: **University Hospital, Antwerp** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** 6-mercaptopurine

## Key facts

- **NCT ID:** NCT05506332
- **Lead sponsor:** University Hospital, Antwerp
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506332, "Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05506332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*